DexCom, Inc. Aktie News

DexCom, Inc. (NASDAQ:DXCM ) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Danielle Antalffy - UBS Securities Robbie Marcus - J.P. Morgan Larry Biegelsen - Wells ...

Dexcom stock plunged late Thursday after the company raised its sales outlook for the year, but not enough to satisfy investors.

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #dexcom--DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic1 basis. U.S. revenue and international revenue both grew 24% on a reported basis and inter...

The value of the “global medical device market” is expected to jump from over $500 billion last year to nearly $800 billion “by 2030.” According to the World Health Organization, “a medical device can be any instrument, apparatus, implement, machine, appliance, implant, reagent for in vitro use, software, material or other similar or related article.

Dexcom stock is in a buy zone ahead of earnings next week. Shares rallied after the company launched a prescription-free glucose monitoring device.

Metabolic health is all the rage, helped by the advent of weight-loss drugs and continuous glucose monitors. Can they change disease forever?

DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust growth in revenue and operating income, warranting its high valuation multiples. DexCom has strong growth catalysts, including the launch of Stelo, which is expected to contribute to significant revenue...

The latest employment figures saw indices rise. However, losses earlier in the week persist as investors remain cautious of the Fed's stance on interest rate adjustments.